Alpha-MSH
Alpha-Melanocyte Stimulating Hormone
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
An endogenous 13-amino-acid peptide with limited exogenous human investigational evidence.
Plain English
Available human information is limited to investigational study and protocol records.
Overview
An endogenous 13-amino-acid peptide. Exogenous human evidence is limited to investigational studies and registered protocols.
Research Summary
NCT00004496 is a completed Phase 1 Alpha-MSH study. NCT06293664 is a registered protocol with no posted results; it supports protocol/status only, not efficacy or established safety.
Research Areas
- Skin pigmentation
- Appetite regulation
- Anti-inflammatory signaling
- Neuroprotection
- Sexual function
- Immune modulation
Legal Status by Region
- United States
- No FDA-approved Alpha-MSH therapeutic product.
- United Kingdom
- Research only
- Australia
- Research only
- Canada
- Research only
Citations & Sources
- Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure
Registry NCT00004496
- Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes
Registry NCT06293664